Achillion Pharmaceuticals Inc (ACHN), Tenax Therapeutics Inc (TENX): Peter Kolchinsky’s Latest Equity Moves

RA Capital Management has continued the sale of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) shares. In a recent wave of reductions, the fund has dumped approximately 2.37 million shares in 10 transactions at prices varying between $10.95 and $11.29 apiece, according to a recent Form 4 filing. As a result, RA Capital Management is left holding 8.03 million shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). In another move, the fund’s manager, Peter Kolchinsky, has initiated a position in Tenax Therapeutics Inc (NASDAQ:TENX). According to a recent filing with the Securities and Exchange Commission, RA Capital has acquired 2.26 million shares, which give it control over 8.1% of the company’s common stock.

Peter Kolchinsky

While Kolchinsky has been dumping Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) shares, Stephen Dubois has been building a new position for his fund during the second quarter of 2014. In its latest 13F filing, Camber Capital Management has disclosed ownership of 5.8 million shares worth $43.9 million. Bain Capital, the manager of Brookside Capital, has also initiated a position during the same period of time and has amassed 2.24 million shares valued at more than $17 million. Daniel Gold, on the other hand, has chosen to reduce his exposure to Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) and has slashed his stake by almost a third. His fund, QVT Financial, was left with 7.39 million shares worth in excess of $55.9 million.

No other fund that we track has invested in Tenax Therapeutics Inc (NASDAQ:TENX). The company has a market cap of $104 million and does not pay a dividend. No revenues were registered during the three months ending July 31, 2014 and Tenax Therapeutics Inc (NASDAQ:TENX) has posted a loss of $0.08 per share. The loss is expected to widen to $0.12 per share during the current quarter and no revenues is expected to be announced. On September 22, the company announced the start of Phase 3 testing of levosimendan, which is expected to reduce morbidity and mortality in cardiac surgery patients who risk developing low cardiac output syndrome.

Disclosure: none.